SuperworthIN8BIO market cap INAB
Share price times shares outstanding: what the whole company sells for, since 2021.
- Today, Oct 23, 2026
- $10.4M
- Highest close in our data
- $158.1M
- Nov 2021
IN8BIO is worth $10.4M at the close on Oct 23, 2026, at $1.05 a share.
That is up 7% over the last year and down 93% over five years.
Its highest close in our data was $158.1M in Nov 2021.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $10.4M | $6.4M | $18.4M | +0% |
| 2025 | $10.3M | $5.6M | $23.4M | −47% |
| 2024 | $19.6M | $10.5M | $59.1M | −56% |
| 2023 | $44.1M | $23.4M | $96.4M | −22% |
| 2022 | $56.6M | $27.9M | $81.4M | −31% |
| 2021 | $82.3M | $82.3M | $158.1M | n/a |
Against its peers
Companies in Healthcare nearest IN8BIO's size, closest first, today.
| Company | Market cap |
|---|---|
| INABIN8BIO | $10.4M |
| NEPHNephros | $38.3M |
| ATNMActinium Pharmaceuticals | $47.8M |
| APTAlpha Pro Tech | $56.7M |
| SPROSpero Therapeutics | $64.6M |
| LFVNLifevantage | $73.4M |
| ICCCImmucell | $93.1M |
| KEQUKewaunee Scientific | $94.9M |
| Peer median | $64.6M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on IN8BIO
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.